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Abstract
Background: This phase 1b study assessed the maximum tolerated dose (MTD), safety, and pharmacokinetics of
motesanib (a small-molecule antagonist of VEGF receptors 1, 2, and 3; platelet-derived growth factor receptor; and
Kit) administered once daily (QD) or twice daily (BID) in combination with erlotinib and gemcitabine in patients
with solid tumors.
Methods: Patients received weekly intravenous gemcitabine (1000 mg/m
2) and erlotinib (100 mg QD) alone
(control cohort) or in combination with motesanib (50 mg QD, 75 mg BID, 125 mg QD, or 100 mg QD; cohorts 1-
4); or erlotinib (150 mg QD) in combination with motesanib (100 or 125 mg QD; cohorts 5 and 6).
Results: Fifty-six patients were enrolled and received protocol-specified treatment. Dose-limiting toxicities occurred
in 11 patients in cohorts 1 (n = 2), 2 (n = 4), 3 (n = 3), and 6 (n = 2). The MTD of motesanib in combination with
gemcitabine and erlotinib was 100 mg QD. Motesanib 125 mg QD was tolerable only in combination with
erlotinib alone. Frequently occurring motesanib-related adverse events included diarrhea (n = 19), nausea (n = 18),
vomiting (n = 13), and fatigue (n = 12), which were mostly of worst grade < 3. The pharmacokinetics of motesanib
was not markedly affected by coadministration of gemcitabine and erlotinib, or erlotinib alone. Erlotinib exposure,
however, appeared lower after coadministration with gemcitabine and/or motesanib. Of 49 evaluable patients, 1
had a confirmed partial response and 26 had stable disease.
Conclusions: Treatment with motesanib 100 mg QD plus erlotinib and gemcitabine was tolerable. Motesanib 125
mg QD was tolerable only in combination with erlotinib alone.
Trial Registration: ClinicalTrials.gov NCT01235416
Background
The development of targeted therapies has greatly
improved treatment for many types of cancers [1]. Spe-
cifically, inhibitors of vascular endothelial growth factor
(VEGF) signaling, including monoclonal antibodies tar-
geting VEGF and small molecules targeting VEGF
receptors (VEGFR), have demonstrated efficacy in the
treatment of a variety of solid tumors [2-5]. Similarly,
inhibitors of the epidermal growth factor receptor
(EGFR) have shown clinical efficacy in the same setting
[6-8].
In an effort to increase treatment benefits, combina-
tions of targeted therapies are currently being explored.
In phase 1 and 2 studies of advanced non—small cell
lung cancer (NSCLC), treatment with the VEGF inhibi-
tor bevacizumab plus erlotinib resulted in response rates
of 17.5% to 20.0% [9-11]. In a phase 3 study of patients
with advanced NSCLC in whom first-line therapy pre-
viously failed [12], treatment with this combination
resulted in improved progression-free survival (3.4 vs
1.7 mo; hazard ratio [HR], 0.62; 95% confidence interval
[CI], 0.52-0.75; P < 0.0001) and response rate (12.6% vs
6.2%; P = 0.006) compared with patients who received
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was observed (9.3 vs 9.2 mo; HR, 0.97; 95% CI, 0.80-
1.18; P = 0.75). Erlotinib (100 mg/day) plus gemcitabine
is indicated in the first-line treatment of locally
advanced, unresectable or metastatic pancreatic cancer
[13]. Potentially, the addition of a VEGF pathway inhibi-
tor might improve outcomes beyond that achieved with
erlotinib plus gemcitabine.
Motesanib is an orally administered small-molecule
antagonist of VEGFR 1, 2, and 3; platelet-derived growth
factor receptor; and Kit [14]. In preclinical A431 human
epidermoid carcinoma, HT29 colorectal carcinoma, and
Calu-6 NSCLC xenograft models, administration of
motesanib in combination with the fully human anti-
EGFR monoclonal antibody panitumumab resulted in
greater antitumor activity than single-agent treatment
[15]. In clinical studies conducted in patients with solid
tumors, motesanib has demonstrated antitumor activity
as monotherapy [16,17], in combination with cytotoxic
chemotherapy [18,19], and, in lung and colorectal can-
cers, in combination with panitumumab (a fully human
anti-EGFR antibody) and chemotherapy [19,20]. The
present phase 1b study explored the feasibility of combi-
nation treatment strategies with motesanib, gemcitabine,
and erlotinib in patients with solid tumors. The study
objectives were to determine the target or maximum
tolerated dose (MTD) and to characterize the safety and
pharmacokinetics of motesanib administered once daily
(QD) or twice daily (BID) in combination with erlotinib
and gemcitabine in patients with solid tumors.
Methods
Patients
Eligible patients (aged > 18 years) had histologically or
cytologically documented solid tumors, had an Eastern
Cooperative Oncology Group performance status ≤ 2,
and were candidates for treatment with erlotinib or with
the combination of gemcitabine and erlotinib in the opi-
nion of the investigator. Key exclusion criteria were:
squamous cell NSCLC; hematologic malignancies; large
central thoracic tumor lesions; direct bowel wall inva-
sion (except for primary tumors of the bowel); untreated
or symptomatic brain metastases; primary solid cancers
with no known active disease present and no curative
treatment administered for the last 3 years (except for
curatively treated nonmelanoma skin cancer); history of
bleeding or bleeding diathesis, or arterial or deep vein
thrombosis; myocardial infarction within 1 year of study
enrollment; uncontrolled hypertension (systolic blood
pressure > 145 mmHg and diastolic blood pressure > 85
mmHg); inadequate cardiac, hepatic, renal or hematolo-
gic function; prior treatment with VEGF/VEGFR inhibi-
t o r s ,e r l o t i n i b ,o rg e m c i t a b i n e ;a n ds y s t e m i c
chemotherapy (within 21 days of study enrollment) or
radiation therapy (within 14 days of study enrollment).
All patients provided written informed consent, and
ethical approval was obtained for all study procedures
from each participating center’s independent ethics
committee or institutional review board. The study was
conducted according to the Declaration of Helsinki.
Study design
This was a phase 1b open-label dose-finding study of
motesanib in combination with erlotinib and gemcita-
bine or with erlotinib alone in patients with advanced
solid tumors, conducted at 4 study centers in Australia
and Canada. The primary endpoint was the incidence
of dose-limiting toxicities (DLTs; defined below); the
secondary endpoint was determination of the pharma-
cokinetic profiles of motesanib and erlotinib. The
safety endpoint was the incidence of adverse events.
Tumor response rate, as assessed by Response Evalua-
tion Criteria in Solid Tumors (RECIST) [21] in
patients with measurable disease, was an exploratory
endpoint.
The study enrolled a control cohort (erlotinib 100 mg
QD plus gemcitabine) and four motesanib dose escala-
tion cohorts (cohorts 1-4), in which patients received
motesanib plus erlotinib (100 mg QD) and gemcitabine.
Once the motesanib MTD was determined, cohorts 5
and 6 were enrolled receiving erlotinib (150 mg QD)
plus motesanib at the MTD (cohort 5) or at a higher
dose (cohort 6) (Figure 1). Enrollment of a minimum of
six evaluable patients per cohort was planned. If patients
discontinued the study before week 5 for any reason
other than a DLT, additional patients could be enrolled
to meet this goal. The selected motesanib doses (50 mg
QD, 100 mg QD, 125 mg QD, and 75 mg BID) were
based on the tolerability profiles of motesanib adminis-
tered as monotherapy [16] and in combination with
gemcitabine [18] that were obtained in previous studies.
The BID dosing regimen is expected to achieve higher
predose motesanib concentrations in the plasma than
QD dosing owing to the higher total dose administered
and more frequent dosing.
Treatment, dose escalation and maximum tolerated dose
Patients in the control cohort and cohorts 1 to 4
received erlotinib (100 mg QD throughout the study)
and gemcitabine (1000 mg/m
2) intravenously weekly for
7 weeks (cycle 1) or 3 weeks (cycles 2-11), followed by 1
week of rest. Treatment continued until the end of week
48 (11 cycles), or until disea s ep r o g r e s s i o n ,d e a t h ,o r
unacceptable toxicity occurred. Motesanib administra-
t i o n( i nc o h o r t s1 - 4 )b e g a no nd a y2o fw e e k2o ft h e
first cycle and continued throughout the study. Patients
experiencing continuous clinical benefit (stable disease
or response) at the end of 48 weeks were eligible to
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protocol.
Patients enrolled in cohort 1 received an initial dose of
m o t e s a n i bo f5 0m gQ D .I f≤ 2 patients experienced a
DLT during the first 5 weeks of treatment, enrollment
into cohort 2 (motesanib 75 mg BID) and cohort 3
(motesanib 125 mg QD) began simultaneously. If ≤ 2
patients in cohort 3 experienced a DLT in the first 5
weeks of treatment, the 125-mg QD dose would be con-
sidered the target once-daily dose. If ≥ 3p a t i e n t si n
cohort 3 had a DLT in that time frame, cohort 4 (mote-
sanib 100 mg QD) was enrolled. The 100-mg QD dose
would be considered the motesanib MTD if ≤ 2 patients
in cohort 4 had a DLT in the first 5 weeks of treatment.
After the MTD of motesanib was established, patients
were enrolled in two additional cohorts receiving a
higher dose of erlotinib (150 mg QD) plus motesanib at
the MTD (100 mg QD; cohort 5) or at a higher dose
(125 mg QD; cohort 6) without gemcitabine. Enrollment
into cohort 6 started only after the lower motesanib
dose administered in cohort 5 was determined to be
safe in combination with erlotinib 150 mg QD.
Motesanib and erlotinib treatment was modified or
withheld according to protocol-specified rules. Briefly,
motesanib treatment was withheld for suspected or
related grade 3 toxicity (other than hypertension) not
adequately controlled with supportive care, or treat-
ment-related grade 4 toxicity. In patients with sympto-
matic hypertension that required immediate or urgent
management, motesanib treatment was withheld and
antihypertensive medications were initiated or opti-
mized. In patients with erlotinib-related toxicity, the
erlotinib dose could be decreased in 50-mg decrements
(no dose re-escalation was allowed).
Patients were permanently withdrawn from treatment
if motesanib was withheld for > 3 continuous weeks, if
more than two 25-mg dose reductions were required, or
if symptomatic grade 4 venous thrombosis or grade 3 or
Figure 1 Study schema.
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tinib and gemcitabine could be modified based on pro-
tocol-specified rules.
Adverse events and dose-limiting toxicities
All adverse events were graded by the investigator
according to National Cancer Institute Common Termi-
nology Criteria for Adverse Events (CTCAE) version 3.0.
All adverse events were classified according to related-
ness to treatment and seriousness. Events were consid-
ered related based on the investigator’s assessment that
t h ee v e n tm a yp o s s i b l yh a v eb e e nc a u s e db yt h et r e a t -
ment. Adverse events typically considered to be related
to motesanib (or erlotinib) included events common to
the pharmacologic class of VEGFR or multikinase (or
EGFR) inhibitors and events that have been previously
associated with motesanib (or erlotinib). A DLT was
defined as treatment-related grade 3 fatigue for ≥ 7d a y s
or grade 4 fatigue; grade 3 or 4 nausea/vomiting despite
maximum supportive care; grade 3 neutropenia with
fever > 38.5°C or grade 4 neutropenia; grade 4 thrombo-
cytopenia for ≥ 7 days; grade 4 anemia; grade 4 hyper-
tension; alanine aminotransferase or aspartate
aminotransferase > 10 times the upper limit of normal;
grade 3 rash for ≥ 7 days despite maximum supportive
care or grade 4 rash; grade 3 diarrhea for ≥ 7d a y s
despite maximum supportive care or grade 4 diarrhea;
or any other treatment-related hematologic or nonhe-
matologic grade 3 or 4 toxicity (except alopecia) occur-
ring in the first 5 weeks of treatment.
Pharmacokinetic analyses
Plasma samples for erlotinib pharmacokinetic analysis
were collected predose and at 0.25, 0.5, 1, 2, 4, and 6
hours postdose on study day 8 (week 2) and predose on
study day 9 (24 hours after day 8 dose) to ensure that
steady state was reached. Plasma samples for both erlo-
tinib and motesanib pharmacokinetic analysis were col-
lected predose on study days 10 and 12; predose and at
0 . 2 5 ,0 . 5 ,1 ,2 ,4 ,6 ,a n d1 2h o u r s( B I Dc o h o r to n l y )
postdose on study day 15 (week 3); and predose on
study day 16 (24 hours post day 15 dose).
Plasma concentrations of motesanib were analyzed
using a validated liquid chromatography/tandem mass
spectrometry (LC-MS/MS) method with a lower limit of
quantitation (LLOQ) of 0.2 ng/mL (Cedra Corp., Austin,
TX). Erlotinib concentrations were also assessed using a
validated LC-MS/MS procedure (LLOQ, 50 ng/mL;
Charles River Laboratories, Worcester, MA, and Shrews-
bury, MA).
Pharmacokinetic parameter estimates were calculated
according to standard noncompartmental methods using
WinNonlin software (version 5.1.1; Pharsight Corpora-
tion, Mountain View, CA) and summarized by dose
level. For both motesanib and erlotinib, maximum
observed plasma concentration (Cmax)a n dt h et i m et o
reach Cmax (tmax) were taken directly from the plasma
concentration-time data. The area under the concentra-
tion versus time curve (AUC) from time 0 to 24 hours
(AUC0—24) after dosing was calculated using the linear-
log trapezoidal rule. For the BID cohort, AUC0—24
values for motesanib were determined by 2 × AUC0—12.
The terminal elimination rate constant (lZ)w a sd e t e r -
mined by linear regression of the natural logarithms of
plasma concentrations versus time during the terminal
phase; the corresponding t1/2 was calculated.
To assess the effect of motesanib administration on
erlotinib exposure with or without gemcitabine, geo-
metric least squares means (GLSM) and the ratio of
G L S Mb e t w e e nw e e k3( w i t hm o t e s a n i b )a n dw e e k2
(erlotinib alone at steady state) were calculated for Cmax
and AUC0—24 using the SAS PROC MIXED procedure
(SAS for Windows, version 9.1, WIN_PRO platform;
SAS Institute Inc., Cary, NC). The GLSM were calcu-
lated by first obtaining the least squares means for the
log-transformed Cmax values (logCmax)a n dA U C 0—24
values (logAUC0—24) for weeks 3 and 2, and then con-
verting these values back to the original scale. The ratio
and 90% confidence interval (CI) of GLSM was calcu-
lated by first estimating the difference (and 90% CI) in
the least squares means between weeks 3 and 2 for
logCmax and logAUC0—24, and then converting the num-
bers back to their original scale. The pharmacokinetic
analysis included all patients who received motesanib
and erlotinib with or without gemcitabine and who had
evaluable plasma samples; the GLSM analysis included
only patients with available pharmacokinetic parameter
data for the protocol-specified treatment.
Tumor response
Tumor assessments were performed using computed
tomography or magnetic resonance imaging at baseline
and at least every 12 weeks after the initial scan and
included all sites of disease. Objective response was con-
firmed at least 4 weeks after the initial scan. Tumor
assessments were performed by the investigator accord-
ing to RECIST [21]. The analysis of response included
all patients with measurable disease at baseline.
Statistical analysis
The planned minimum sample size was 24 patients (6
evaluable patients in a minimum of 3 dose-escalation
cohorts and a control cohort). Cohort enrollment could
be expanded to ensure that at least 6 evaluable patients
were enrolled or in the event of unresolved safety, phar-
macokinetic, or other concerns. The overall sample size
could be further increased if additional dose cohorts
were considered justified based on the results from the
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endpoints, the mean, standard error or standard devia-
tion (SD); median; 25th and 75th percentiles; and mini-
mum and maximum were calculated. For discrete data,
the frequency and percent distributions were calculated.
No formal comparisons between cohorts were per-
formed. The data were analyzed using SAS software ver-
sion 8.2 (SAS Institute, Cary, NC). The statistical
analysis was completed on March 20, 2009. The safety
analysis set included all patients who received at least 1
dose of study therapy.
Results
Patients
From September 2006 to September 2007, 57 patients
were enrolled in the study and 56 patients received
study treatment, including eight patients in the control
cohort. Demographic and baseline characteristics are
summarized in Table 1. The main reasons for disconti-
nuing treatment with motesanib, erlotinib, or gemcita-
bine were disease progression (n = 25, n = 37, n = 24;
r e s p e c t i v e l y ) ,a d v e r s ee v e n t s( n=9 ,n=7 ,n=8 ) ,a n d
withdrawal of consent (n = 4, n = 5, n = 5).
At the time of data cutoff (November 2008), one
patient continued to receive treatment. In cohorts
receiving motesanib, erlotinib, and gemcitabine, the
median treatment duration was 75 days (range, 17-653
days) for motesanib and 75.5 days (range, 1-346 days)
for erlotinib; the median number of gemcitabine infu-
sions was 10 (range, 3-54). In cohorts receiving motesa-
nib and erlotinib only, the median treatment duration
was 70.5 days (range, 19-244 days) for motesanib and
78.5 days (range, 27-252 days) for erlotinib. Median fol-
low-up time was 18 weeks (range, 2-82 weeks).
Dose escalation, dose-limiting toxicities, and maximum
tolerated dose
Seven patients were enrolled in cohort 1 (motesanib 50
mg QD), two of whom experienced DLTs (one patient
had grade 4 febrile neutropenia and one had grade 3
fatigue). Consequently, cohorts 2 (75 mg BID) and 3
(125 mg QD) were opened simultaneously and enrolled
Table 1 Demographic and clinical characteristics of study patients
Gemcitabine +
Erlotinib
(100 mg QD)
Motesanib + Gemcitabine + Erlotinib
(100 mg QD)
Motesanib + Erlotinib
(150 mg QD)
Characteristic Control
(n = 8)
Motesanib
50 mg QD
(n = 7)
Motesanib
100 mg QD
(n = 8)
Motesanib
125 mg QD
(n = 10)
Motesanib
75 mg BID
(n = 9)
Motesanib
100 mg QD
(n = 7)
Motesanib
125 mg QD
(n = 7)
Sex, n
Women 3 6 3 5 7 7 2
Men 5 1 5 5 2 0 5
Race, n
White 7 7 6 10 6 6 7
Asian 0 0 2 0 3 1 0
Japanese 1 0 0 0 0 0 0
Median age, y (range) 62 (36-71) 66 (46-80) 50 (40-75) 59.5 (36-77) 53 (21-76) 50 (35-76) 55 (46-73)
ECOG performance status, n
0 3 154455
1 5 535522
2 0 101000
Disease stage, n
I 0 001000
I I 0 001001
III 0 0 1 0 1 0 0
I V 8 778876
Tumor type, n
Colon 3 0 1 1 1 1 0
Pancreatic 1 1 0 1 0 0 2
Breast 0 0 1 0 0 2 1
Melanoma 0 0 1 1 1 0 0
Non—small
cell lung 0 1 1 0 1 0 0
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patients experienced DLTs (including grade 3 nausea,
tumor necrosis, and rash; and grade 4 neutropenia). In
cohort 3, three patients had DLTs (including grade 3
nausea, vomiting, fatigue, cholecystitis, jaundice, sub-
dural hematoma, and cognitive disorder); therefore,
cohort 4 administering a lower dose of motesanib (100
mg QD) was opened and nine patients were enrolled
(one patient did not receive treatment). No DLTs
occurred and thus the MTD of motesanib in combina-
tion with gemcitabine and erlotinib was established as
100 mg QD. Subsequently, cohorts 5 and 6 were
opened, enrolling seven patients each. In cohort 5,
patients received erlotinib 150 mg QD plus motesanib
at the MTD (100 mg QD); in cohort 6, patients received
erlotinib 150 mg QD plus motesanib 125 mg QD. DLTs
occurred only in cohort 6 (one patient had grade 3 fati-
gue and one had grade 3 rash). The MTD for motesanib
in combination with erlotinib only was established as
125 mg QD. Enrollment in cohort 2 was suspended as a
result of the increased risk of cholecystitis observed at
the 75-mg BID dose level in other motesanib studies
[16,20].
Adverse events
Of the 48 patients who received motesanib, 40 (83%)
experienced motesanib-related adverse events, most
commonly diarrhea, nausea, vomiting, fatigue, and anor-
exia (Table 2). Several adverse events of specific interest
considered related to motesanib treatment occurred and
included grade ≤ 3 hypertension, grade 3 and 4 neutro-
penia, grade 3 deep vein thrombosis, grade 4 pulmonary
embolism, and grade 3 cholecystitis (Table 2). Twenty-
three patients experienced grade ≥ 3 adverse events
related to motesanib treatment, primarily in cohort 3
(eight of 10 patients; 125 mg QD motesanib plus gemci-
tabine and erlotinib) and in cohort 6 (four of seven
patients; 125 mg QD motesanib plus erlotinib). No
grade 5 motesanib-related adverse events occurred dur-
ing the study. Fourteen patients (29%) had serious mote-
sanib-related adverse events, which included nausea (n =
5), vomiting (n = 5), deep vein thrombosis (n = 2),
Table 1 Demographic and clinical characteristics of study patients (Continued)
Squamous cell
head/neck 0 1 1 0 0 1 0
Medullary
thyroid 0 0 1 1 0 0 1
Carcinoma
unknown
origin 1 0 0 1 0 0 0
Ovarian 0 1 0 0 1 0 0
Prostate 0 0 0 0 0 0 2
Stomach 0 1 0 0 1 0 0
Other
a 3 225431
Prior therapy, n
b
0 3 106211
1 t o 2 1 231411
3 t o 4 1 221013
≥ 5 3 232342
Prior chemotherapy, n
0 3 228211
1 t o 2 1 331423
3 t o 4 1 121111
≥ 5 3 110232
Prior radiotherapy, n
0 5 336554
1 t o 2 3 333312
3 t o 4 0 120111
≥ 5 0 001000
BID = twice daily; ECOG = Eastern Cooperative Oncology Group; QD = once daily
aIncludes tumor types occurring in ≤ 2% of patients.
bAll cancer therapies patients received before study enrollment.
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tumor necrosis (n = 2). Of those, seven patients were
enrolled in cohort 3. Adverse events with a worst grade
of 3 or higher considered related to gemcitabine or erlo-
tinib occurring in the control cohort were anemia
(grade 3; n = 1), febrile neutropenia (grade 3; n = 1),
fatigue (grade 3; n = 1), and rash (grade 3; n = 1). There
were no incidences of hypertension or thromboembolic
events in the control cohort.
Of the 56 patients who received erlotinib, 54 (96%)
experienced erlotinib-related adverse events, most fre-
quently rash (n = 42), diarrhea (n = 35), nausea (n =
23), anorexia (n = 16), vomiting (n = 15), and fatigue (n
= 14). Among patients in cohorts 5 and 6 (motesanib
plus erlotinib without gemcitabine), the most common
adverse events were diarrhea (n = 10), rash (n = 9), nau-
sea (n = 7), fatigue (n = 5), anorexia (n = 4), and vomit-
ing (n = 4).
Adverse events leading to study discontinuation
included pulmonary embolism (n = 3) and fatigue (n =
2). One patient discontinued the study because of ser-
ious grade 3 cholecystitis. No patients withdrew from
the study because of thrombotic events. Eight deaths
occurred during the study, none of which were consid-
ered related to any study drug treatment. Six were
attributed to disease progression; the causes for the
other two deaths were pneumonia and sepsis. Overall,
24 patients (50%) had at least one interruption in
Table 2 Patient incidence of motesanib-related adverse events
Motesanib + Gemcitabine + Erlotinib
(100 mg QD)
Motesanib + Erlotinib
(150 mg QD)
Patient Incidence Motesanib
50 mg QD
(n = 7)
Motesanib
100 mg QD
(n = 8)
Motesanib
125 mg QD
(n = 10)
Motesanib
75 mg BID
(n = 9)
Motesanib
100 mg QD
(n = 7)
Motesanib
125 mg QD
(n = 7)
Any adverse event, n 3 8 9 7 7 6
Adverse events of grade 3, n
a 036334
Diarrhea 0 1 1 0 2 1
Nausea 0 0 3 1 0 0
Vomiting 0 1 2 0 0 0
Fatigue 0 1 0 0 0 2
Tumor necrosis 0 0 0 1 1 0
Deep vein
thrombosis 0 0 2 0 0 0
Abnormal liver
function test 0 1 0 0 0 1
Neutropenia 0 1 0 0 1 0
Adverse events of grade 4, n
Pulmonary 1 0 2 1 0 0
embolism 0 0 2 0 0 0
Febrile neutropenia 1 0 0 0 0 0
Neutropenia 0 0 0 1 0 0
Adverse events of interest and highest (worst) grade, n
Hypertension 0 0 0 2 1 2
Grade 3 0 0 0 0 0 1
Thrombophlebitis (all grade 3) 0 0 1 0 0 0
Gallbladder toxicity 0 0 2
b 01
c 0
Grade 3 0 0 1 0 0 0
Hemorrhagic events 0 0 1
d 01
e 0
Grade 3 0 0 1 0 0 0
Cardiac toxicity (all grade 3) 0 1
f 0000
BID = twice daily; QD = once daily
aFor motesanib-related adverse events only those grade 3 events are listed that occurred in ≥ 2 patients.
bCholecystitis (n = 1; grade 3) and gallbladder enlargement (n = 1; grade 1)
cGallbladder enlargement (grade 2)
dSubdural hematoma
eEpistaxis (grade 1)
fCongestive heart failure and pulmonary edema
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reduction as a result of adverse events. Among patients
who received motesanib plus gemcitabine and erlotinib,
35% had at least one dose interruption and 26% had at
least one dose reduction due to adverse events (36% and
36%, respectively, among patients who received motesa-
nib plus erlotinib).
Pharmacokinetics
Pharmacokinetic parameter estimates of motesanib in
combination with 100 mg QD erlotinib and gemcitabine
or in combination with 150 mg QD erlotinib alone are
shown in Figure 2 according to motesanib dose cohort.
After QD or BID administration in combination with
100 mg erlotinib and gemcitabine at week 3, motesanib
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Figure 2 Motesanib pharmacokinetic (PK) parameter estimates across cohorts. Individual (circles) and median (lines) values are shown by
motesanib dose cohort for Cmax (A), AUC0—24 (B), and C24 (C) values after oral administration of motesanib in combination with 100 mg QD
erlotinib and gemcitabine or 150 mg QD erlotinib alone on week 3. Data for all subjects who received the protocol-specified treatment are
shown.
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Page 8 of 13was rapidly absorbed. Overall median tmax values ranged
from 0.6 to 2 hours. The mean estimated terminal elimi-
nation half-life (t1/2, z)r a n g e df r o m4 . 8t o8 . 6h o u r s .A t
week 3, the Cmax,A U C 0—24,a n dC max at 24 hours post-
dose (C24)i nt h ed o s er a n g eo f5 0t o1 2 5m gQ Dw e r e
generally within the range of values observed in a study
of motesanib monotherapy [16]. Similarly, estimates of
Cmax,A U C 0—24,a n dC 24 at the 75-mg BID dose were
within the range observed at this dose in a study of
motesanib in combination with gemcitabine [18].
After QD administration in combination with 150 mg
erlotinib at week 3, motesanib was rapidly absorbed.
The overall median tmax value was 2 hours, and the
mean estimated t1/2, z for motesanib ranged from 6.0 to
7.7 hours. The Cmax values at week 3 for the 100 mg
QD dose were within the range of values observed in a
study of motesanib monotherapy [16], but the AUC0—24,
and C24 values were slightly (< 2-fold) higher, although
high intersubject variability was observed in this study
(Figure 2). However, the Cmax, AUC0—24, and C24 values
at week 3 for the 125-mg QD dose were within the
range observed at this dose in a monotherapy study
[16].
Following QD administration of 100 mg erlotinib in
combination with gemcitabine, erlotinib had a median
tmax ranging from 2 to 6 hours at week 2. Mean t1/2, z
ranged from 17 to 33 hours. After QD administration of
erlotinib in combination with gemcitabine and motesa-
nib at week 3, erlotinib had an overall median tmax value
of 2 hours. Mean t1/2, z values ranged from 12 to 19
hours. Based on the GLSM estimates for the ratio of
week 3 to week 2 erlotinib parameter values, erlotinib
exposure was approximately 20% to 35% as assessed by
Cmax and 10% to 50% as assessed by AUC0—24
(Table 3). The reduction in erlotinib exposure did not
appear to be dependent on motesanib dose.
Following QD administration of 150 mg erlotinib at
week 2, erlotinib had a median tmax ranging from 1 to 3
hours. Mean t1/2, z ranged from 25 to 33 hours. After
QD administration of erlotinib and motesanib at week
3, erlotinib had median tmax values from 2 to 4 hours
and a mean t1/2, z value of approximately 8 hours. Based
on the GLSM estimates for the ratio of week 3 to week
2 erlotinib parameter values, erlotinib exposure was
reduced by approximately 40% lower for Cmax and
approximately 50% lower for AUC0—24 (Table 3), but
did not appear to be dependent on motesanib dose.
Motesanib trough concentrations were similar across
patients at each dose level tested, regardless of treat-
ment. Erlotinib trough concentrations appeared to
decrease in the presence of motesanib compared with
erlotinib alone.
Tumor response
Of 49 patients with measurable disease (per RECIST) at
baseline, one patient with NSCLC (75 mg motesanib
BID plus gemcitabine and erlotinib) achieved a con-
firmed partial response. Three patients with the follow-
ing tumor types had unconfirmed partial responses:
pancreatic cancer (control), NSCLC (50 mg QD motesa-
nib plus gemcitabine and erlotinib), and anaplastic thyr-
oid cancer (100 mg QD motesanib plus gemcitabine and
erlotinib). The latter patient had a 93% reduction from
baseline in tumor dimensions at the first tumor assess-
ment (week 12) but was subsequently assessed as having
progressive disease (week 24) based on an increase in
tumor dimensions of > 20% per RECIST. At that time,
tumor dimensions were still reduced by 89% from base-
line. Twenty-six patients, primarily in the cohorts that
received the triple combination as well as in the control,
had stable disease as a best tumor response; of those,
three had durable stable disease with a duration of ≥ 24
weeks from study day 1 (125 mg QD and 75 mg BID
motesanib plus gemcitabine and erlotinib, 125 mg QD
motesanib plus erlotinib; n = 1 each). The most com-
mon tumor types in patients who achieved stable disease
were colon cancer (n = 4) and NSCLC (n = 2). Maxi-
mum changes from baseline in tumor measurements are
Table 3 Pharmacokinetics of erlotinib after single-dose administration in combination with motesanib
AUC0—24 Cmax
Dose Cohort n GLSM Ratio
Week 3: Week 2
a
(90% CI)
n GLSM Ratio
Week 3: Week 2
a
(90% CI)
50 mg motesanib QD + 100 mg erlotinib QD + gemcitabine 7 0.49 (0.25-0.96) 7 0.65 (0.39-1.08)
100 mg motesanib QD + 100 mg erlotinib QD + gemcitabine 7 0.53 (0.25-1.11) 8 0.82 (0.49-1.37)
125 mg motesanib QD + 100 mg erlotinib QD + gemcitabine 9 0.91 (0.48-1.73) 10 0.73 (0.48-1.09)
75 mg motesanib BID + 100 mg erlotinib QD + gemcitabine 9 0.52 (0.37-0.74) 9 0.75 (0.54-1.05)
100 mg motesanib QD + 150 mg erlotinib QD 7 0.46 (0.34-0.60) 7 0.59 (0.41-0.84)
125 mg motesanib QD + 150 mg erlotinib QD 7 0.46 (0.19-1.13) 7 0.61 (0.50-0.73)
AUC0—24 = area under the curve from time 0-24 h; BID = twice daily; Cmax = peak plasma concentration; CI = confidence interval; GLSM = geometric least
squares means; QD = once daily
aWeek 3, erlotinib plus motesanib treatment; week 2, erlotinib treatment only.
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Page 9 of 13shown in Figure 3, indicating that most responses of
stable disease were associated with modest tumor
regression. A total of 25 patients (44%) had reductions
in tumor size from baseline.
Discussion
T h ep r i m a r yo b j e c t i v e so ft h ec u r r e n ts t u d yw e r et o
determine the target dose or MTD and characterize the
safety of motesanib administered QD or BID in combi-
nation with erlotinib and gemcitabine in patients with
advanced solid tumors. In previous studies, 125 mg QD
was the MTD of motesanib administered as monother-
apy [16] and was the target dose in combination with
gemcitabine [18]. In the current study, the MTD for
motesanib plus erlotinib and gemcitabine was estab-
lished as 100 mg QD. At a dose of 125 mg QD, motesa-
nib was not tolerable in the triple combination and was
associated with a higher incidence of DLTs and serious
adverse events, including thromboembolic events (pul-
monary embolism and deep vein thrombosis), which
were not observed in other dosing cohorts. However, at
the 125-mg QD dose motesanib was tolerable when
combined with erlotinib (150 mg QD) only. The mote-
sanib 75-mg BID dosing cohort was suspended when
an increased risk of cholecystitis was found at that
dose level in other studies of motesanib as a mono-
therapy [16,17] or in combination with carboplatin/
paclitaxel and an EGFR inhibitor [20]. Cholecystitis is
not considered a common class effect of VEGF(R)
inhibitors, although three other small-molecule inhibi-
tors (sunitinib, cediranib, and sorafenib) have reported
its occurrence [2,22,23]. No gallbladder toxicities were
observed in the BID cohort of the present study, but
one patient (with malignant mesothelioma) in the
motesanib 125-mg QD cohort experienced serious
grade 3 cholecystitis. The patient presented with
abdominal pain approximately 26 days after initiation
of motesanib treatment and was diagnosed with acute
acalculous cholecystitis. A laparoscopic cholecystect-
omy was performed, which resulted in complete reso-
lution of the symptoms, and the patient withdrew from
the study. The cholecystitis was considered to be
related to motesanib treatment and not related to erlo-
tinib or gemcitabine treatment.
Figure 3 Maximum change from baseline in the sum of the longest diameters of target lesions (as assessed by the investigator per
RECIST). “Unevaluable” refers to patients who had a response assessment before the scheduled first assessment without an additional
postbaseline assessment. 1 = 50 mg QD + gemcitabine/erlotinib; 2 = 75 mg BID + gemcitabine/erlotinib; 3 = 125 mg QD + gemcitabine/
erlotinib; 4 = 100 mg QD + gemcitabine/erlotinib; 5 = 100 mg QD + erlotinib; 6 = 125 mg QD + erlotinib.
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quently occurring motesanib-related adverse events
(diarrhea, nausea, vomiting, fatigue, and anorexia) were
consistent with those observed in other studies of mote-
sanib as monotherapy [16,17], in combination with che-
motherapy [18], and in combination with an EGFR
inhibitor and chemotherapy [20,24]. Skin toxicities are
frequently associated with the use of many EGFR inhibi-
tors [25]. In the present study, the incidence of erloti-
nib-related skin rash was 75%, which is similar to the
72% incidence rate that was reported in a phase 3 com-
bination study of erlotinib and gemcitabine for the treat-
ment of metastatic pancreatic cancer [13]. There did not
appear to be any exacerbation of erlotinib-related skin
toxicity with motesanib coadministration. A number of
motesanib-related adverse events of interest occurred,
including hypertension, thromboembolic events, chole-
cystitis, and neutropenia. Most of these events are con-
sidered class effects [26] and have been described
previously with motesanib treatment [16-20,24]. In the
current study we observed an increased incidence and
severity of these adverse events in the 125-mg QD
cohort of the triple combination arm.
The pharmacokinetics of motesanib were not mark-
edly affected by the combination with erlotinib and
gemcitabine, or with erlotinib only. However, erlotinib
Cmax and AUC0—24 appeared to be lower following
either combination treatment (motesanib plus erlotinib
and gemcitabine or motesanib plus erlotinib alone).
Pharmacokinetic interactions between motesanib and
erlotinib may have occurred because motesanib is an
inhibitor of cytochrome P450 (CYP) 3A4 and an inducer
of CYP1A2 [27]. Erlotinib is metabolized at least in part
by CYP3A4 and CYP1A2 [28]. Hence, the observed
decrease in erlotinib Cmax and AUC0—24 after coadmi-
nistration with motesanib may have resulted from
induction of CYP1A2 by motesanib. It has previously
been reported that coadministration of gefitinib and sor-
afenib results in reduced exposure to gefitinib but not
sorafenib [29]. Pharmacokinetic interactions with gemci-
tabine were not expected because it is primarily metabo-
lized by deoxycytidine deaminase [30]. Taken together
the data show that although there are no pharmacoki-
netic interactions between gemcitabine and either mote-
sanib or erlotinib, interactions occur when motesanib
and erlotinib are coadministered. Dose modifications of
erlotinib may require further investigation when given
in combination with motesanib.
In the present study, tumor response was an explora-
tory endpoint. One confirmed and three unconfirmed
partial responses were observed, all of which but one
unconfirmed response occurred in the triple combina-
tion arm. Most patients (70%) receiving motesanib 125
mg QD plus gemcitabine and erlotinib achieved stable
disease, but this cohort also experienced more toxicities.
Furthermore, reductions in tumor size associated with
stable disease were largely modest across treatment
cohorts. The risk/benefit ratio of treatment with a
VEGF pathway inhibitor plus an EGFR inhibitor and
chemotherapy has recently been highlighted in an
ongoing phase 2 study in NSCLC, in which 48% of
patients achieved a partial response and 22% achieved
stable disease. However, 36% of patients had grade 4
adverse events [31]. Recent studies have suggested that
the combination of a VEGF pathway inhibitor and an
EGFR inhibitor may provide clinical benefit in some set-
tings, but the results have not been uniformly positive
and further investigation is, therefore, warranted. In a
phase 3 study, second-line treatment with bevacizumab
plus erlotinib in NSCLC did not extend overall survival
(the primary endpoint) compared with erlotinib plus
placebo although progression-free survival and objective
response rate were improved [12]. In another phase 3
study in patients with NSCLC, treatment with bevacizu-
mab plus erlotinib as maintenance therapy improved
progression-free survival compared with bevacizumab
among patients who received bevacizumab plus che-
motherapy as first-line treatment [32]. A phase 3 study
of bevacizumab plus erlotinib and gemcitabine in
patients with metastatic pancreatic adenocarcinoma did
not show an increase in overall survival, compared with
control (erlotinib, gemcitabine, and placebo), but
reported a significant increase in progression-free survi-
val [33].
Conclusions
In conclusion, in patients with solid tumors, motesanib
in combination with gemcitabine and erlotinib was tol-
erable at the MTD of 100 mg QD. Motesanib 125 mg
QD was tolerable in combination with erlotinib only.
The pharmacokinetics of motesanib were not markedly
affected by combination treatment with erlotinib and
gemcitabine; however, erlotinib exposure was reduced
when coadministered with motesanib. Tumor responses
were observed but additional studies are required to
evaluate whether the triple combination of motesanib
plus gemcitabine and erlotinib or the double combina-
tion of motesanib plus erlotinib provides clinical benefit
in specific tumor types.
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